Citigroup Inc. Sells 21,595 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

Citigroup Inc. lessened its holdings in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 23.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 70,338 shares of the biotechnology company's stock after selling 21,595 shares during the quarter. Citigroup Inc. owned 0.16% of United Therapeutics worth $21,683,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. raised its position in United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company's stock worth $1,374,001,000 after acquiring an additional 15,312 shares in the last quarter. AQR Capital Management LLC raised its position in United Therapeutics by 0.8% during the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock worth $344,176,000 after acquiring an additional 7,710 shares in the last quarter. Assetmark Inc. raised its position in United Therapeutics by 20.8% during the first quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company's stock worth $159,823,000 after acquiring an additional 89,290 shares in the last quarter. Northern Trust Corp raised its position in United Therapeutics by 29.1% during the fourth quarter. Northern Trust Corp now owns 488,854 shares of the biotechnology company's stock worth $172,487,000 after acquiring an additional 110,298 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in United Therapeutics by 1.9% during the fourth quarter. Janus Henderson Group PLC now owns 468,996 shares of the biotechnology company's stock worth $165,490,000 after acquiring an additional 8,577 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other news, Director Nilda Mesa sold 645 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director directly owned 4,883 shares in the company, valued at approximately $1,416,021.17. This trade represents a 11.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $300.00, for a total transaction of $3,300,000.00. Following the completion of the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $11,034,300. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 81,681 shares of company stock valued at $24,618,359. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Price Performance

UTHR traded up $2.34 on Thursday, hitting $312.06. 586,994 shares of the stock were exchanged, compared to its average volume of 676,653. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $417.82. The business has a 50-day moving average of $295.25 and a two-hundred day moving average of $309.63. The firm has a market capitalization of $14.08 billion, a price-to-earnings ratio of 12.18, a PEG ratio of 4.69 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%. The firm had revenue of $798.60 million for the quarter, compared to the consensus estimate of $802.13 million. During the same period in the prior year, the company earned $5.85 EPS. The company's revenue for the quarter was up 11.7% compared to the same quarter last year. Equities research analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on UTHR shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of United Therapeutics in a report on Thursday. UBS Group upped their price objective on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday. Morgan Stanley decreased their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a report on Thursday, July 10th. HC Wainwright set a $400.00 price objective on shares of United Therapeutics and gave the company a "buy" rating in a report on Thursday, July 31st. Finally, Wells Fargo & Company decreased their price objective on shares of United Therapeutics from $314.00 to $295.00 and set an "equal weight" rating on the stock in a report on Thursday, July 31st. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $382.00.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.